A Phase 3, Randomized, Three-Cycle, Double-Blind, Placebo-Controlled Study to Evaluate Induction of Secretory Conversion of Endometrium and Withdrawal Bleeding After Administration of TX-12-002-HR in Estrogen-Primed Women With Secondary Amenorrhoea
Phase of Trial: Phase III
Latest Information Update: 10 May 2018
Price : $35 *
At a glance
- Drugs Progesterone (Primary)
- Indications Amenorrhoea
- Focus Registrational; Therapeutic Use
- Acronyms SPRY
- Sponsors TherapeuticsMD
- 10 May 2018 Last checked against ClinicalTrials.gov record.
- 19 Nov 2014 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov record.
- 04 Jan 2014 New trial record